Navigation Links
Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
Date:12/19/2007

ZURICH, Switzerland, December 19 /PRNewswire/ -- An exclusive license for the development and commercialisation of a drug delivery system for lung infections in Cystic Fibrosis patients was signed today. As part of the agreement, aRigen Pharmaceuticals Inc., Japan transferred relevant rights to Axentis Pharma AG of Switzerland. The EMEA has already granted orphan drug status to the licensed technology and a phase II clinical trial will be initiated by Axentis Pharma AG in early 2008.

Axentis Pharma AG (Switzerland) and aRigen Pharmaceuticals, Inc. (Japan) announced today the signature of a license agreement for the development of therapy against lung infections in Cystic Fibrosis patients. Under the terms of the agreement Axentis Pharma AG purchased from aRigen Pharmaceuticals, Inc. an exclusive license for the development and commercialisation of ARB-CF0223 worldwide except Japan and Korea. ARB-CF0223 is a fully patented, innovative encapsulating drug delivery system for the treatment of pulmonary infections in patients with Cystic Fibrosis. The system has an improved safety profile, higher efficacy and lower doses, and also reduces the frequency and severity of exacerbations compared to current treatments for pulmonary infections in patients with Cystic Fibrosis. As part of the agreement aRigen Pharmaceuticals, Inc. received shares of Axentis Pharma plus an undisclosed sum in cash.

Jorg Zielasek, President of Axentis Pharma AG, commented that: "The purchase of the license from aRigen Pharmaceuticals grants Axentis the right to further develop and commercialise an extremely promising treatment for chronic lung inflammation, the most severe consequence of Cystic Fibrosis. The agreement means that Axentis can now initiate an immediate phase II clinical trial in Germany. The design of the study has already been approved by the EMEA, which has also granted orphan drug status to ARB-CF0223. This is a very promising prospect for both Cystic Fibrosis
'/>"/>

SOURCE Axentis Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
2. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
3. PTC Therapeutics Announces Encouraging Additional Phase 2 Results of PTC124 in Cystic Fibrosis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
6. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
7. Pharsight Achieves First License Sale for Public-Source Database
8. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
9. Niceware International Announces Licensed Vendor Status with ICCBBA, Inc. to Provide ISBT 128-compliant Software
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... , May 26, 2015  Alere Inc. (NYSE: ... of its failure to timely file its Quarterly Report on ... (the "Form 10-Q"), it has received a notice from the ... not in compliance with the NYSE,s continued listing requirements under ... NYSE Listed Company Manual. The reason for ...
(Date:5/26/2015)... NJ (PRWEB) May 26, 2015 OHAUS ... balances and scales, is set to release a new ... of quality-driven laboratory instruments. For over a century, the ... in weighing technology throughout the world. Now in ... has gone Beyond Weighing to include water quality measurement. ...
(Date:5/26/2015)... 26, 2015 Pharmaco-Kinesis Corporation (PKC) announced today ... at Shutters on the Beach in Santa ... of the Company,s innovative Metronomic Biofeedback Pump (MBP), a ... chemotherapy over time to a target site of the ... biofeedback system in real-time.  ...
(Date:5/26/2015)... , May 26, 2015 Mr. Kevin Xu ... thanks President Barack Obama and President Bill ... time of loss of Dr. Rongxiang Xu , Kevin,s ... a leader ahead of his time, Dr. Xu,s commitment to ... leave a legacy that will not be forgotten. As a ...
Breaking Biology Technology:OHAUS Corporation to Release New Water Analysis Meters in 2015 2OHAUS Corporation to Release New Water Analysis Meters in 2015 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 2Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 3Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 4Pharmaco-Kinesis Corporation Convenes Third Neuro-Oncology Clinical Advisory Board Meeting 5Dr. Rongxiang Xu, Beyond A Legend 2
... Guide New Service Offering, PHILADELPHIA, Feb. 7 ... Alzheimer,s risk assessment service,with the appointment of a medical ... leading laboratory testing companies in the world., "Our ... accurate,information about their genetic risk, help them understand and ...
... Calif., Feb. 7 Documents,detailing the California stem ... relations firm reveal an agency,leadership worried about the ... secret by channeling it through an outside law ... said today., The stem cell institute, a ...
... In a speech to be delivered Tuesday,February 12th, ... Conference,at the New York Grand Hyatt Hotel, U.S. ... Thompson, will propose that,prevention is the solution for ... together experts from throughout the health care industry,to ...
Cached Biology Technology:Smart Genetics Announces Plans to Launch a New Alzheimer's Risk Assessment Service 2Smart Genetics Announces Plans to Launch a New Alzheimer's Risk Assessment Service 3'Crisis Management' PR Firm's Advice to Stem Cell Agency Laundered Through Law Firm to Avoid Scrutiny 2'Crisis Management' PR Firm's Advice to Stem Cell Agency Laundered Through Law Firm to Avoid Scrutiny 3U.S. Preventive Medicine National Policy Advisor Gov. Tommy Thompson to Propose Prevention is the Solution at UBS Global Health Services Conference 2
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/5/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, reminds investors and media that  Mr. David Tunnell ... SECURE CONNEXIONS AMERICA 2015, held in Washington DC ... conference is organized into a series of nine session tracks. ... Fraud: Where is the Trust in Cyberspace? and will ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... new study in the July 18 issue of The ... more harmful than their unpigmented relatives. A group of ... have discovered that the molecules that give certain bugs ... cells called neutrophils. , Scientists and clinicians have known ...
... Microbiologists seeking ways to eliminate pollution from waterways with ... in freshwater ponds can generate electricity. They present their ... American Society for Microbiology. , "The bacteria are capable ... used to operate small electronic devices. As long as ...
... of that group of diseases, affects 500 000 people in ... Leishmania infantum, transmitted by sand fly bites. There is no ... if no treatment is given. In the most heavily affected ... acts as parasite reservoir for humans. Development of a vaccine ...
Cached Biology News:Pollution-eating bacteria produce electricity 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 2Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 3Visceral Leishmaniasis: Successful Vaccine Trial In Dogs 4
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
...
Biology Products: